Drugs / anti-CD19 IL10/IL15 CAR-NK
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06707259 | Dec 2024 → Dec 2026 expected | B-cell non-Hodgkin lymphoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-CD19 IL10/IL15 CAR-NK | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06707259 ↗ |
| Modality | Cell therapy | “cord blood-derived NK cells” NCT06707259 ↗ |
| Route | Intravenous | “All subjects were intravenously administrated with IL-10/IL-15 CD19-CAR NK” NCT06707259 ↗ |
| Target | CD19 | “anti-CD19-IL10/IL-15 CAR” NCT06707259 ↗ |